药物洗脱支架在慢性肢体威胁性缺血膝下介入治疗中的应用不足
基于2016至2017年全国再入院数据库,纳入1817例因慢性肢体威胁性缺血行膝下支架介入的患者,其中1056例(58.1%)使用药物洗脱支架。药物洗脱支架使用率在不同医院间差异约44%,且与较低的靶肢体大截肢和靶肢体血运重建复合结局风险相关(aHR=0.75,95%CI=0.62-0.92,p=0.004)。
要点
- 膝下介入治疗慢性肢体威胁性缺血中,药物洗脱支架使用率仅58.1%。
- 教学医院及中等、大床位规模医院更倾向于使用药物洗脱支架。
- 药物洗脱支架与较低的靶肢体大截肢和血运重建复合结局风险相关。
核心结论
- 在因慢性肢体威胁性缺血行膝下介入治疗的患者中,尽管有证据支持药物洗脱支架优于裸金属支架,药物洗脱支架仍存在显著使用不足。
- 与裸金属支架相比,药物洗脱支架与主要复合结局改善相关。
研究设计与样本
- 利用2016至2017年全国再入院数据库,通过ICD-10编码提取因慢性肢体威胁性缺血行膝下支架(裸金属支架和药物洗脱支架)介入治疗的患者。
- 采用以医院ID为随机效应的多水平逻辑回归评估药物洗脱支架使用情况,主要结局为靶肢体大截肢和靶肢体血运重建的复合终点,使用多变量Cox比例风险回归校正混杂因素。
- 共纳入1817例患者。
主要发现
- 1817例患者中,1056例(58.1%)接受药物洗脱支架。
- 2016至2017年间药物洗脱支架使用率稳定(相对变化+2.5%,p-trend=0.867)。
- 药物洗脱支架使用率在教学医院较高(aOR=1.28,95%CI=1.03-1.61,p=0.029),在中等床位规模医院(aOR=3.13,95%CI=2.17-4.55,p≤0.001)和大床位规模医院(aOR=1.56,95%CI=1.14-2.17,p=0.005)较高。
- 组内相关系数为0.44,提示任意两家随机医院间药物洗脱支架使用率变异约44%。
- 与裸金属支架相比,药物洗脱支架与较低的主要复合结局发生率相关(aHR=0.75,95%CI=0.62-0.92,p=0.004)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Multiple randomized clinical trials have shown superiority of drug-eluting stents (DES) over bare-metal stents (BMS) for infrapopliteal disease. However, real-world data on DES utilization and outcomes in infrapopliteal chronic limb-threatening ischemia (CLTI) patients are unknown. MATERIALS AND METHODS: We utilized the Nationwide Readmission Database (NRD) from 2016 to 2017 to extract patients undergoing infrapopliteal intervention with stents (BMS and DES) for CLTI using appropriate ICD-10 codes. Multilevel logistic regression with hospital ID as random effect was used to assess DES utilization. Primary outcome was the composite of target limb major amputation (TLmajA) and target limb revascularization (TLR). Multivariate Cox-proportional hazard regression was used to adjust for confounders. RESULTS: Our study included a total of 1817 patients. Of these patients, 1056 patients (58.1%) received DES; DES utilization was stable (relative change: +2.5%, p-trend: 0.867) between 2016 and 2017 and was higher in teaching hospitals (adjusted odds ratio [aOR] = 1.28, 95% CI = 1.03-1.61, p=0.029] and medium (aOR = 3.13, 95% CI = 2.17-4.55, p≤0.001) and large (aOR = 1.56, 95% CI = 1.14-2.17, p=0.005) bed-sized hospitals. Inter-class correlation was 0.44 suggesting ~44% variation in DES utilization between any 2 random hospitals; DES was associated with lower rate of the primary composite outcome (aHR = 0.75, 95% CI = 0.62-0.92, p=0.004) compared with BMS. CONCLUSION: In patients undergoing infrapopliteal intervention for CLTI, DES demonstrated significant underutilization despite supportive evidence of their superiority compared with BMS; DES was associated with improvement in the primary composite outcome compared with BMS.
引用
- Zuzek Z, Arora S, Helmy I, et al. Underutilization of Drug-Eluting Stents in Infrapopliteal Intervention for Chronic Limb-Threatening Ischemia. J Endovasc Ther. 2022. PMID: 35075941. doi:10.1177/15266028211068763
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。